Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised phase 3 trial

BACKGROUND: In the ongoing phase 3 CheckMate 214 trial, nivolumab plus ipilimumab (NIVO+IPI) demonstrated superior efficacy over sunitinib (SUN) in patients with previously untreated IMDC intermediate/poor-risk advanced renal cell carcinoma (aRCC) with a manageable safety profile. We assessed effica...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Lancet Oncol
Asıl Yazarlar: Motzer, Robert J, Rini, Brian I, McDermott, David F, Frontera, Osvaldo Arén, Hammers, Hans J, Carducci, Michael A, Salman, Pamela, Escudier, Bernard, Beuselinck, Benoit, Amin, Asim, Porta, Camillo, George, Saby, Neiman, Victoria, Bracarda, Sergio, Tykodi, Scott S, Barthélémy, Philippe, Leibowitz-Amit, Raya, Plimack, Elizabeth R, Oosting, Sjoukje F, Redman, Bruce, Melichar, Bohuslav, Powles, Thomas, Nathan, Paul, Oudard, Stéphane, Pook, David, Choueiri, Toni K, Donskov, Frede, Grimm, Marc-Oliver, Gurney, Howard, Heng, Daniel Y C, Kollmannsberger, Christian K, Harrison, Michael R, Tomita, Yoshihiko, Duran, Ignacio, Grünwald, Viktor, McHenry, M Brent, Mekan, Sabeen, Tannir, Nizar M
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2019
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7497870/
https://ncbi.nlm.nih.gov/pubmed/31427204
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(19)30413-9
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller